131 related articles for article (PubMed ID: 16467734)
21. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
Iino M
Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
[TBL] [Abstract][Full Text] [Related]
22. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
[TBL] [Abstract][Full Text] [Related]
23. Clofarabine.
Pui CH; Jeha S; Kirkpatrick P
Nat Rev Drug Discov; 2005 May; 4(5):369-70. PubMed ID: 15902772
[No Abstract] [Full Text] [Related]
24. Anaphylactoid reaction to high-dose methotrexate and re-administration after a successful desensitization.
Caldeira T; Costa V; Silva I; Oliva T; Norton L
Pediatr Hematol Oncol; 2008 Mar; 25(2):131-4. PubMed ID: 18363180
[TBL] [Abstract][Full Text] [Related]
25. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
[TBL] [Abstract][Full Text] [Related]
26. Nelarabine.
Sanford M; Lyseng-Williamson KA
Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine in the treatment of refractory T-cell malignant diseases.
Kline J; Larson RA
Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
29. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
30. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
31. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
32. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Horie R; Watanabe T; Umezawa K
Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
[TBL] [Abstract][Full Text] [Related]
33. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Gilbert J; Carducci MA; Baker SD; Dees EC; Donehower R
Invest New Drugs; 2006 Nov; 24(6):499-508. PubMed ID: 16788861
[TBL] [Abstract][Full Text] [Related]
34. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
[TBL] [Abstract][Full Text] [Related]
35. Multifocal necrotizing leukoencephalopathy: An unusual complication of acute leukemia.
Robb J; Chalmers L; Rojiani A; Chamberlain M
Arch Neurol; 2006 Jul; 63(7):1028-9. PubMed ID: 16831976
[No Abstract] [Full Text] [Related]
36. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of nelarabine in indolent leukemias.
Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
[TBL] [Abstract][Full Text] [Related]
38. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
39. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
40. Acute T cell lymphoblastic leukemia in the recipient of a renal transplant from a donor with malignant lymphoma.
Kowal M; Hus M; Dmoszynska A; Kocki J; Grzasko N
Acta Haematol; 2008; 119(3):187-9. PubMed ID: 18536518
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
